Suppr超能文献

生物活性肽:从基础研究到临床试验与商业化

Bioactive Peptides: From Basic Research to Clinical Trials and Commercialization.

作者信息

Duffuler Pauline, Bhullar Khushwant S, de Campos Zani Stepheny C, Wu Jianping

机构信息

Department of Agricultural Food & Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada.

Department of Pharmacology, University of Alberta, Edmonton, Alberta T6G 2P5, Canada.

出版信息

J Agric Food Chem. 2022 Mar 30;70(12):3585-3595. doi: 10.1021/acs.jafc.1c06289. Epub 2022 Mar 18.

Abstract

Chronic diseases, including metabolic diseases, have become a worldwide public health issue. Research regarding the use of bioactive peptides or protein hydrolysates derived from food, as the diet-based strategies for the prevention and mitigation of chronic diseases, has increased exponentially in the past decades. Numerous and studies report the efficacy and safety of food-derived bioactive peptides and protein hydrolysates as antihypertensive, anti-inflammatory, antidiabetic, and antioxidant agents. However, despite promising preclinical results, an inadequate understanding of their mechanisms of action and pharmacokinetics restrict their clinical translation. Commercialization of bioactive peptides can be further hindered due to scarce information regarding their efficacy, safety, bitter taste, as well as the lack of a cost-effective method of production. This review provides an overview of the current clinical evidence and challenges to commercial applications of food-derived bioactive peptides and protein hydrolysates for the prevention and alleviation of chronic diseases.

摘要

包括代谢性疾病在内的慢性病已成为一个全球性的公共卫生问题。在过去几十年中,关于使用源自食物的生物活性肽或蛋白质水解物作为基于饮食的慢性病预防和缓解策略的研究呈指数级增长。大量研究报告了源自食物的生物活性肽和蛋白质水解物作为抗高血压、抗炎、抗糖尿病和抗氧化剂的功效和安全性。然而,尽管临床前结果很有前景,但对其作用机制和药代动力学的了解不足限制了它们的临床转化。由于关于其功效、安全性、苦味的信息稀缺,以及缺乏具有成本效益的生产方法,生物活性肽的商业化可能会受到进一步阻碍。本综述概述了目前关于源自食物的生物活性肽和蛋白质水解物预防和缓解慢性病的临床证据以及商业应用面临的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验